# BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

> **NCT06794008** · PHASE2 · RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus
- Inflammatory Myopathy
- Systemic Sclerosis (SSc)
- ANCA-associated Vasculitis
- IgG4-Related Diseases
- Antiphospholipid Syndrome
- Acquired Thrombotic Thrombocytopenic Purpura
- Behcet Disease
- Sjogren Syndrome

## Interventions

- **DRUG:** BCMA-CD19 CAR-T therapy

## Key facts

- **NCT ID:** NCT06794008
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-26
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06794008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06794008, "BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06794008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*